MedPath

Comparing surgical treatment outcomes in patients with different levels of drug-resistant tuberculosis

Not Applicable
Completed
Conditions
Pulmonary tuberculosis
Infections and Infestations
Registration Number
ISRCTN71922508
Lead Sponsor
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
1259
Inclusion Criteria

Every patient with a diagnosis of drug-resistant M tuberculosis admitted in our clinic between 2011 and 2017 was included in this study.

Exclusion Criteria

Patients with unknown drug resistance admitted in our clinic between 2011 and 2017

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br> 1. Presence of cavities in pulmonary tissue (CV+/CV-) determined with CT scan/digital X-ray on discharge from the hospital<br> 2. Presence of M tuberculosis assessed using AFB smear test of sputum (AFB+/AFB-) using sputum fluorescent microscopy and culture method on discharge from the hospital<br>
Secondary Outcome Measures
NameTimeMethod
<br> 1. Presence of cavities in pulmonary tissue (CV+/CV-) determined with CT scan/digital X-ray every year for 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge<br> 2. Presence of M tuberculosis assessed using AFB smear test of sputum (AFB+/AFB-) using sputum fluorescent microscopy and culture method every year for 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge<br> 3. TB relapse assessed by clinical follow-up up to 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge.<br> 4. Degree of disability assessed by checking patients' documentation and anamnesis (patentient's account of medical history) during follow-up up to 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge.<br> 5. Survival assessed by follow-up up to 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge.<br>
© Copyright 2025. All Rights Reserved by MedPath